Home LiteratureArticle Details
PMID: 19956155 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable?

British journal of cancer ·Vol. 101 Suppl 2 ·2009-12-03 ·Pages S115-24

Abdel-Rahman M, Stockton D, Rachet B, Hakulinen T, Coleman MP

Abstract

To estimate the number of deaths among cancer patients diagnosed in Great Britain that would be avoidable within 5 years of diagnosis if the mean (or highest) survival in Europe for patients diagnosed during 1985-1989, 1990-1994 and 1995-1999 were achieved. Five-year relative survival for cancers in Great Britain compared with that from other countries in the EUROCARE-2, -3 and -4 studies. Calculation of excess deaths (those more than expected from mortality in the general population) that would be avoidable among cancer patients in Britain if relative survival were the same as in Europe. Great Britain (England, Wales, Scotland) and 13 other European countries. 2.8 million adults diagnosed in Britain with 1 of 39 cancers during 1985-1989 (followed up to 1994), 1990-1994 (followed up to 1999) and 1995-1999 (followed up to 2003). Annual number of avoidable deaths within 5 years of diagnosis. Percentage of the excess (cancer-related) deaths among cancer patients that would be avoidable. Compared with the mean European 5-year relative survival, the largest numbers of avoidable deaths for patients diagnosed during 1985-1989 were for cancers of the breast (about 18% of the excess mortality from this cancer, 7541 deaths), prostate (14%, 4285), colon (9%, 4090), stomach (8%, 3483) and lung (2%, 3548). For 1990-1994, the largest numbers of avoidable deaths were for cancers of the prostate (20%, 7335), breast (15%, 6165), colon (9%, 4376), stomach (9%, 3672), lung (2%, 3735) and kidney (22%, 2644). For 1995-1999, most of the avoidable deaths were for cancers of the prostate (17%, 5758), breast (15%, 5475), lung (3%, 4923), colon (10%, 4295), stomach (9%, 3137) and kidney (21%, 2686).Overall, some 6600-7500 premature deaths would have been avoided each year among cancer patients diagnosed in Britain during 1985-1999 if the mean survival in Europe had been achieved. This represents 6-7% of cancer-related mortality. Compared with the highest European survival, avoidable premature mortality among cancer patients fell from about 12 800 deaths a year (12.2% of cancer-related mortality) to about 11 400 deaths a year (10.6%) over the same period.A large component of the avoidable mortality is due to prostate cancer: excluding this cancer from comparison with the European mean survival reduces the annual number of avoidable deaths by 1000-1500, and the percentage of excess mortality by up to 1%. Compared with the highest survival, the annual number of avoidable deaths would be 1500-2000 fewer, and 1-2% lower as a percentage of excess mortality, but the overall trend in avoidable premature mortality among cancer patients would be similar, falling from 11.4% (1985-1989) to 10.3% (1990-1994) and 9.7% for those diagnosed during 1995-1999.For several cancers, survival in Britain was slightly higher than the mean survival in Europe; this represented some 110-180 premature deaths avoided each year during the period 1985-2003. Avoidable premature mortality among cancer patients diagnosed in Britain during 1985-1999 has represented 6-7% of cancer-related mortality compared with the mean survival in Europe. Compared with the highest levels of survival in Europe, the reduction from 12.2% to 10.6% of cancer-related mortality reflects small but steady progress over the period 1985-2003.

MeSH Terms
Adolescent Adult Aged Aged, 80 and over Europe/epidemiology Female Humans Male Middle Aged Neoplasms/mortality Time Factors United Kingdom/epidemiology
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Abdel-Rahman M
Cancer Research UK Cancer Survival Group, Non-Communicable Disease Epidemiology Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, UK.
Stockton D
Rachet B
Hakulinen T
Coleman M P
References (21)
21 references, click to expand
  1. Cancer survival in Britain is poorer than that of her comparable European neighbours.
    BMJ. 1999 Aug 21;319(7208):461-2 PMID: 10454383
  2. Relative survival and the estimation of net survival: elements for further discussion.
    Stat Med. 1990 May;9(5):529-38 PMID: 2349404
  3. Opinion: why the variation in breast cancer survival in Europe?
    Breast Cancer Res. 1999;1(1):22-6 PMID: 11250678
  4. Cancer survival.
    Lancet. 2000 Nov 4;356(9241):1611 PMID: 11075801
  5. The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis.
    Ann Oncol. 2003;14 Suppl 5:v14-27 PMID: 14684498
  6. Statistical methods in cancer research. Volume IV. Descriptive epidemiology.
    IARC Sci Publ. 1994;(128):1-302 PMID: 7698823
  7. Interpreting survival differences and trends.
    Tumori. 1997 Jan-Feb;83(1):9-16 PMID: 9152463
  8. Electronic availability of EUROCARE-3 data: a tool for further analysis.
    Ann Oncol. 2003;14 Suppl 5:v150-5 PMID: 14684504
  9. Survival and reduction in mortality from breast cancer. "Avoided deaths" may not be useful for predicting mortality reductions from cancer.
    BMJ. 2000 Dec 9;321(7274):1471-2 PMID: 11187947
  10. How many deaths have been avoided through improvements in cancer survival?
    BMJ. 2000 Apr 1;320(7239):895-8 PMID: 10741993
  11. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century.
    Ann Oncol. 2003;14 Suppl 5:v128-49 PMID: 14684503
  12. The cure of cancer: a European perspective.
    Eur J Cancer. 2009 Apr;45(6):1067-79 PMID: 19131242
  13. EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary.
    Ann Oncol. 2003;14 Suppl 5:v61-118 PMID: 14684501
  14. Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCISproject): an epidemiological study.
    Lancet. 2004 Dec 11-17;364(9451):2097-105 PMID: 15589307
  15. Survival of patients with colon cancer in Europe: a cautionary tale.
    Colorectal Dis. 2000 Jul;2(4):190-2 PMID: 23578076
  16. Survival trends in European cancer patients diagnosed from 1988 to 1999.
    Eur J Cancer. 2009 Apr;45(6):1042-66 PMID: 19124239
  17. Questions remain over validity of EUROCARE data.
    Lancet. 2009 Sep 19;374(9694):964-5 PMID: 19774705
  18. Socioeconomic inequalities in cancer survival in England and Wales.
    Cancer. 2001 Jan 1;91(1 Suppl):208-16 PMID: 11148581
  19. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study.
    Lancet Oncol. 2007 Sep;8(9):773-83 PMID: 17714991
  20. Mixture models for cancer survival analysis: application to population-based data with covariates.
    Stat Med. 1999 Feb 28;18(4):441-54 PMID: 10070685
  21. Calculation of survival rates for cancer.
    Proc Staff Meet Mayo Clin. 1950 May 24;25(11):270-86 PMID: 15417650
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
1532-1827
Published
2009-12-03
Pages
S115-24
Language
English
Region
England
NLM ID
0370635
PMCID
PMC2790713
Subset
IM
Grants
Cancer Research UK · 11700 · United Kingdom
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]